Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota, USA.
Center for Sleep Medicine, Mayo Clinic, Rochester, Minnesota, USA.
J Clin Psychiatry. 2020 Feb 25;81(2):19r12924. doi: 10.4088/JCP.19r12924.
Varenicline has been shown to be safe and effective in improving abstinence in smokers. However, results from randomized, placebo-controlled trials using varenicline for alcohol use disorders (AUDs) are inconsistent. The present systematic review and meta-analyses aimed to ascertain whether varenicline improves drinking-related outcomes in subjects with AUDs.
Ovid, Embase, and Scopus databases were queried using the search terms varenicline, alcoholism, alcohol-related disorders, and drinking behavior for English-language publications until August 29, 2019, of randomized, placebo-controlled trials in humans.
A total of 197 articles were identified by the literature search. Studies of subjects with heavy drinking or alcohol dependence/AUD that reported alcohol use-related outcomes were examined.
Weighted mean difference (WMD), standardized mean difference (SMD), and 95% CIs were calculated. The primary outcome of interest was percentage of heavy drinking days. Secondary outcomes included the number of drinks per drinking day, percentage of days abstinent, and change in alcohol craving.
Ten studies (n = 731, 66.6% male, 55.1% smokers) were included in the systematic review. In meta-analyses, no significant differences in percentage of heavy drinking days (n = 597; WMD = -1.09; 95% CI, -4.86 to 2.69; I² = 22%), number of drinks per drinking day (n = 570; WMD = -0.71; 95% CI, -1.44 to 0.03; I² = 0%), or percentage of days abstinent (n = 439; WMD = 3.89; 95% CI, -1.25 to 9.02; I² = 0%) were noted with varenicline use. Overall risk of bias was low. A statistically significant decrease in craving was observed (n = 436; SMD = -0.63; 95% CI, -1.18 to -0.08; I² = 84%).
In the present systematic review and meta-analyses, varenicline was shown to reduce alcohol craving but not improve drinking-related outcomes in subjects with AUDs.
已证实伐伦克林可安全有效地改善吸烟者的戒烟效果。然而,使用伐伦克林治疗酒精使用障碍(AUD)的随机、安慰剂对照试验结果并不一致。本系统评价和荟萃分析旨在确定伐伦克林是否能改善 AUD 患者的饮酒相关结局。
使用 varenicline、alcoholism、alcohol-related disorders 和 drinking behavior 等英文检索词,检索 Ovid、Embase 和 Scopus 数据库,检索时间截至 2019 年 8 月 29 日,纳入评估伐伦克林对 AUD 患者饮酒相关结局影响的人类随机、安慰剂对照试验。
通过文献检索共确定 197 篇文章。对报告饮酒相关结局的重度饮酒或酒精依赖/ AUD 受试者的研究进行了评估。
计算加权均数差(WMD)、标准化均数差(SMD)和 95%置信区间(CI)。主要观察指标为重度饮酒天数百分比。次要结局指标包括每日饮酒量、无饮酒天数百分比和酒精渴求变化。
系统评价纳入 10 项研究(n = 731,66.6%为男性,55.1%为吸烟者)。荟萃分析结果显示,伐伦克林组与安慰剂组相比,重度饮酒天数百分比(n = 597;WMD = -1.09;95% CI,-4.86 至 2.69;I² = 22%)、每日饮酒量(n = 570;WMD = -0.71;95% CI,-1.44 至 0.03;I² = 0%)或无饮酒天数百分比(n = 439;WMD = 3.89;95% CI,-1.25 至 9.02;I² = 0%)差异均无统计学意义。总体偏倚风险较低。伐伦克林组的渴求总体显著降低(n = 436;SMD = -0.63;95% CI,-1.18 至 -0.08;I² = 84%)。
本系统评价和荟萃分析表明,伐伦克林可降低 AUD 患者的酒精渴求,但不能改善其饮酒相关结局。